Soleno Therapeutics, Inc.   Report issue

For profit Phase 2 Phase 3
Founded: Redwood City CA United States (1999)
Status: No NME R&D (1999)

Organization Overview

First Clinical Trial
2007
NCT00484029
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Capnia, Inc. | Soleno Therapeutics, Inc.

Active Ingredients

Drugs in Phase 3 Trials (3)

Key: Soleno Therapeutics, Inc. (0) Acquired (3)

atorvastatin (lipitor) (1 trial)

diazoxide choline (12 trials)

fenofibrate (fenoglide) (1 trial)

Drugs in Phase 2 Trials (2)

carbon dioxide (dry ice) (9 trials)

diazoxide (hyperstat) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cluster Headache (Phase 2)

Disease (Phase 2)

Headache (Phase 2)

Migraine Disorders (Phase 2)

Neuralgia (Phase 2)

Prader-Willi Syndrome (Phase 3)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Perennial (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Syndrome (Phase 3)

Temporomandibular Joint Disorders (Phase 2)

Temporomandibular Joint Dysfunction Syndrome (Phase 2)

Trigeminal Neuralgia (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 22
  • # of Trial APIs: 5